Loading the company…
Loading the company…
㈜휴비스트제약
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-09 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Daejeon, founded in 2014. Industry: Bio & Pharma. Revenue for 2025 was ₩55.2bn. It has 91 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2020-06-25 · latest registration 2022-03-30 · newest first
본 발명은 흰점박이꽃무지 유충 추출물을 함유하는 수면개선용 조성물에 관한 것으로, 보다 상세하게는 흰점박이꽃무지 유충 추출물이 수면 개시시간을 단축시키고 수면시간을 연장시킴으로써 수면을 개선시키는 것을 확인함으로써, 부작용 없이 장기간 안전하게 사용할 수 있는 수면개선 조성물의 개발에 기여할 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 41.7 | 55.2 |
| Cost of sales | 15.9 | 19.3 |
| Gross profit (loss) | 25.8 | 35.9 |
| Selling, general and administrative expenses | 22.2 | 30.6 |
| Operating income (loss) | 3.5 | 5.3 |
| Non-operating income | 0.2 | 0.3 |
| Other gains | 0.1 | 0.1 |
| Finance income | 0.1 | 0.0 |
| Other | 0.1 | 0.2 |
| Non-operating expenses | 1.9 | 1.3 |
| Other losses | 0.1 | 0.0 |
| Finance costs | 1.5 | 1.2 |
| Other | 0.4 | 0.1 |
| Profit (loss) before tax | 1.8 | 4.3 |
| Income tax expense | 0.2 | 0.5 |
| Net income (loss) | 1.7 | 3.8 |
Revenue ₩55.2bn, up 32.6% YoY.
Operating margin 9.6% (prior 8.4%).
Net income ₩3.8bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06